This map shows the geographic impact of J Wolter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Wolter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Wolter more than expected).
This network shows the impact of papers produced by J Wolter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Wolter. The network helps show where J Wolter may publish in the future.
Co-authorship network of co-authors of J Wolter
This figure shows the co-authorship network connecting the top 25 collaborators of J Wolter.
A scholar is included among the top collaborators of J Wolter based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with J Wolter. J Wolter is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Ghalie, Richard, et al.. (1995). Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer.. PubMed. 1(1). 40–6.13 indexed citations
Bonomi, P., M. Gale, Jamie Von Roenn, et al.. (1988). Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.. PubMed. 15(2 Suppl 1). 26–33.15 indexed citations
9.
Roenn, Jamie H. Von, Philip Bonomi, M. Gale, et al.. (1988). Sequential hormone therapy for advanced breast cancer.. PubMed. 15(2 Suppl 1). 38–43.5 indexed citations
Willson, James K. V., Matthew Knuiman, Roland T. Skeel, et al.. (1986). Phase II clinical trial of acivicin in advanced breast cancer: an Eastern Cooperative Oncology Group Study.. PubMed. 70(10). 1237–8.3 indexed citations
12.
Ettinger, David S., Daniel Finkelstein, Gregory Harper, et al.. (1985). Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study.. PubMed. 69(9). 1033–4.8 indexed citations
13.
Bonomi, Philip, Dennis Pessis, Mark I. Block, et al.. (1985). Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer.. PubMed. 12(1 Suppl 1). 36–9.29 indexed citations
14.
Kuperminc, Mario, et al.. (1981). Phase II study of vindesine in metastatic malignant melanoma.. PubMed. 65(3-4). 355–6.5 indexed citations
15.
Glass, Andrew G., Wieand Hs, Bernard Fisher, et al.. (1981). Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents.. PubMed. 65(5-6). 363–76.28 indexed citations
Mh, Cohen, David A. Schoenfeld, & J Wolter. (1980). Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma.. PubMed. 64(1). 151–3.18 indexed citations
18.
Hahn, Robert G., et al.. (1979). Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 63(3). 513–5.24 indexed citations
19.
Nj, Vogelzang, et al.. (1978). Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) treatment of non-oat cell bronchogenic carcinoma.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 62(10). 1595–7.9 indexed citations
20.
Bonomi, Philip, Robert E. Slayton, & J Wolter. (1978). Phase II trial adriamycin and cis-dichlorodiammineplatinum(II) in squamous cell, ovarian, and testicular carcinomas.. PubMed. 62(8). 1211–3.11 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.